Clinical Trials Logo

Filter by:
NCT ID: NCT05397743 Recruiting - Clinical trials for Evisceration; Traumatic, Eye

Quality Of Life After Eye Surgical Removal

QOLAE
Start date: May 23, 2022
Phase: N/A
Study type: Interventional

Studies have shown that health-related quality of life (HRQOL) was worse among patients who underwent surgical eye removal compared to the general population in Denmark. A third of eye amputated patients suffered from anxiety and depression. Most of the available evidence on the subject is based on retrospective studies that interviewed patients several years after surgery, which can potentially introduce biases. Moreover, in the literature, there are no data concerning postoperative psychological and visual impact.

NCT ID: NCT05397496 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Start date: October 3, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

NCT ID: NCT05397470 Active, not recruiting - Clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD)

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

Start date: June 16, 2022
Phase: Phase 3
Study type: Interventional

This is a study to evaluate the safety and efficacy of losmapimod in treating participants with Facioscapulohumeral Muscular Dystrophy (FSHD). Participants diagnosed with Facioscapulohumeral muscular dystrophy type 1 (FSHD1) or Facioscapulohumeral muscular dystrophy type 2 (FSHD2) will participate in Part A (Placebo-controlled treatment period) and will be randomized in a 1:1 ratio to receive losmapimod 15 milligrams (mg) or placebo orally twice daily (BID). Upon completion of Part A, participants will have the option to rollover into Part B (open-label extension) to evaluate the long-term safety, tolerability, and efficacy of losmapimod and will receive losmapimod 15 mg orally BID.

NCT ID: NCT05397197 Recruiting - Premature Birth Clinical Trials

Impact of Moderate Preterm Birth on Vocabulary Acquisition

BABYLANG
Start date: October 19, 2022
Phase: N/A
Study type: Interventional

Children born prematurely may present a neurodevelopmental disorder with a language delay diagnosed as early as 2-3 years of age. This situation is not uncommon: each year in France, approximately 35,000 children are born between 32 and 36 weeks of amenorrhea. In our most recent work, we have shown that moderate premature infants show an attenuated cortical response to a vowel change, suggesting a deficit in the cortical encoding of vowels. This work needs to be continued in order to better understand syllable encoding and identify the neuroplasticity mechanisms underlying early speech encoding. The identification of markers to predict language development is essential for the screening of these children at risk of language delay. These children could thus benefit from early adapted care even before the appearance of language deficits.

NCT ID: NCT05396820 Completed - Pain, Acute Clinical Trials

Adaptation of the Motor System to Experimental Pain

KinesioPoint
Start date: September 5, 2022
Phase: N/A
Study type: Interventional

This study aims to measure the impact of an experimental pain on electromyography, kinematics of motion and motor cortical excitability.

NCT ID: NCT05396105 Recruiting - Clinical trials for Hereditary Angioedema

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

RAPIDe-2
Start date: December 28, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks, in patients with HAE due to C1-esterase inhibitor (C1-INH) deficiency (type I/II). The study will enroll patients from Study PHA022121-C201 (NCT04618211) who elect to participate in this extension study and meet the eligibility requirements.

NCT ID: NCT05396066 Recruiting - Clinical trials for ICU Acquired Weakness

Respiratory and Quadriceps Muscle Fatigability After an ICU Acquired Weakness

Start date: June 15, 2022
Phase:
Study type: Observational

Muscle dysfunction can be lead to poor outcomes moreover ICU muscle weakness recovery are not correctly described. The investigators aimed to assess the ability for quadriceps or respiratory muscles to repeat an effort at a maximal loading.

NCT ID: NCT05395897 Active, not recruiting - Psychotropic Drugs Clinical Trials

ORiginal meThodology for Assessing the Impact of the Coronavirus Health Crisis on Psychotropic Drug Use

TORNADO
Start date: January 1, 2023
Phase:
Study type: Observational

The health crisis linked to the coronavirus has had a significant impact on the mental health. The question of the repercussion of this crisis on the consumption of psychotropic drugs is crucial. It is all the more true in France, which was already among the countries with the highest consumption of psychotropic drugs before the crisis. Indeed, an increase in the number of reimbursements for anxiolytic, hypnotic and antidepressant drugs has been highlighted in the context of the health crisis, using data from the health insurance database. To enhance the understanding about the impacts of the health crisis on the use of psychotropic drugs, it is essential to characterize the evolution of the use at the individual level. The main objective is to assess the impact of the coronavirus-related health crisis on the consumption of psychotropic drugs by studying the trajectories of reimbursements. The secondary objective of the project is to evaluate the evolution of problematic consumption of psychotropic drugs in the context of the health crisis.

NCT ID: NCT05395468 Not yet recruiting - Iron-deficiency Clinical Trials

Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.

CaFerIA
Start date: September 2022
Phase:
Study type: Observational

The objective of our work is to predict the value of ferritin from the eye, thus constituting an original, non-invasive diagnostic method of iron deficiency. To be usable in real life, the algorithm must be comparable to the performance of the reference diagnostic test (determination of ferritin), allowing to obtain a sensitivity of about 90% and a specificity > 95%.

NCT ID: NCT05395299 Active, not recruiting - Clinical trials for Prostatic Hyperplasia, Benign

Prostatic Arterial Embolization With SQUID (Ethylene Vinyl Alcohol Copolymer )

SQUID
Start date: November 22, 2022
Phase: N/A
Study type: Interventional

The aim of this pilot study is to analyze the feasibility of prostatic embolization for the treatment of symptomatic benign prostatic hypertrophy with a non adhesive liquid embolic agent (Squid)